We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A once-in-a-decade chance to get rich by investing in FTSE 100 shares?

After lagging overseas stocks for over 10 years, our writer investigates whether FTSE 100 shares could be the smart place for his money today.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

The FTSE 100 index has attracted its fair share of criticism in recent years. Arguably, much of the flak has been warranted.

Recent research from Goldman Sachs has revealed that the Footsie delivered a 6% total annual return over the past decade. Compared to 8% for Europe’s Stoxx 50 and 13% for America’s S&P 500, Britain’s largest shares have been international laggards.

Should you buy GSK shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

However, there are indications the tide could be turning for FTSE 100 stocks. Consequently, UK investors might consider looking closer to home for strong future returns. Here’s why.

A rare bargain opportunity

Using the 12-month forward price-to-earnings (P/E) ratio as a gauge, FTSE 100 shares look remarkably cheap relative to pricier stocks stateside.

UK shares trade at a 55% discount to their US counterparts. This gap is the widest it’s been since 1988 by a considerable margin. Value investors have good reasons to view today as a potential buying opportunity we haven’t seen for many, many years.

However, as a note of caution, this gulf has widened substantially since the 2016 Brexit vote and shows little sign of narrowing. At least for now.

Worryingly, UK-focused equity funds have suffered retail investor outflows for three years on the trot. There’s a risk Britain’s stock market malaise could continue for a while yet. Restoring investor confidence is far from guaranteed.

The stagnation of Japanese stocks for 30 years, starting in the early 1990s, is evidence of how long the suffering can persist in developed equity markets.

Where next for UK shares?

That said, the comparison with Japan only goes so far. Its ‘Lost Decades’ followed the bursting of a huge asset price bubble amid periods of monetary tightening.

By contrast, the UK seems to be heading in the other direction today. Despite holding interest rates at 5% in the last Monetary Policy Committee meeting, the Bank of England indicated it’s on a trajectory towards further easing over the coming months.

Governor Andrew Bailey said interest rates are “now gradually on the path down“. Additional rate cuts could spark some much-needed growth for FTSE 100 share prices.

In this context, I can see the logic behind the latest Goldman Sachs FTSE 100 forecast. The bank predicts the index will surge to 8,800 points within 12 months. As I write, the Footsie’s hovering around the 8,233 level.

A FTSE 100 stock to consider

Identifying which shares in the index appear deeply undervalued can be very lucrative over the long run. One candidate to consider buying is pharma giant GSK (LSE:GSK).

The stock’s forward P/E of 8.64 is well below the average for other companies in the industry and the index as a whole.

GSK also stacks up well on other valuation metrics. A price-to-book (P/B) ratio of 4.4 and price-to-sales (P/S) ratio of 1.8 both indicate a potential bargain.

Granted, long-running litigation concerning the firm’s Zantac heartburn medication continues to cloud the growth outlook. Disappointing sales for the company’s shingles and respiratory syncytial virus (RSV) vaccines are also a cause for concern.

But, I’m pleased to see other areas of the business, including cancer, HIV, and other speciality medicines, are growing fast. The group’s overall revenue performance exceeded expectations in Q2 and FY24 guidance has been upgraded.

Charlie Carman has positions in Goldman Sachs Group and GSK. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

This way, That way, The other way - pointing in different directions
Investing Articles

Investec vs Aberdeen: which is the better income stock to buy?

Aiming to boost the average yield of his income portfolio, Mark Hartley's looking for new income stocks to buy on…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Down 41% since January, this quality S&P 500 stock is stinking out my ISA

The tide's turned against this S&P 500 robotics stock. Is it time to dump it? Or is there a no-brainer…

Read more »

GSK scientist holding lab syringe
Investing Articles

By mid-2027, analysts expect £6,000 in GSK shares to be worth…

GSK shares are currently trading almost 20% below their 2026 highs. Is there potential for a rebound over the next…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Up nearly 1,400% in 5 years! But are Rolls-Royce shares still secretly undervalued?

After skyrocketing, Rolls-Royce shares are now near an all-time high, but could the engineering giant still have more room to…

Read more »

Happy senior couple hugging and enjoying retirement at home
Investing Articles

By mid-2027, analysts expect £5,000 in Barclays shares to be worth…

Barclays shares have outperformed the FTSE 100 by a wide margin over the last year. And City analysts expect to…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Near 5-year lows, here’s what the experts say about the Diageo share price

Ben McPoland's questioning his sanity after investing in Diageo. Where do institutional analysts see its share price heading over the…

Read more »

British Airways cabin crew with mobile device
Investing Articles

Up 165% but still with a P/E of 7.9. Is the IAG share price a generational bargain?

The IAG share price has been on fire for the last two years, delivering some of the biggest returns in…

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Here’s the latest Vodafone share price forecasts for 2027

Up 35% in 12 months, the Vodafone share price is beating the stock market right now, but can this momentum…

Read more »